Why the study?
Does cilazapril improve plasma glucose, insulin, and lipid concentrations in patients with hypertension?
Does cilazapril improve plasma glucose, insulin, and lipid concentrations in patients with hypertension?
Answers are grounded in this paper and cite their sources.
Cilazapril treatment in hypertensive patients improves glucose and insulin metabolism, but these benefits are lost when hydrochlorothiazide is added.
Patients with hypertension tend to be glucose intolerant, hyperinsulinemic, and dyslipedemic. Since all of these changes increase risk of coronary heart disease (CHD), it is important to know what effect antihypertensive treatment has on these variables. The current open-labelled, uncontrolled study was initiated in order to extend our understanding of these issues. This study was performed in 19 patients with hypertension who were started on an angiotensin converting enzyme (ACE)-inhibitor, cilazapril, with hydrochlorothiazide (HC) added if needed to control blood pressure. Plasma glucose and insulin responses to oral glucose and lipid concentrations were measured before, 26, and 52 weeks after starting treatment. Patients treated with either cilazapril (n = 9) or cilazapril + HC (n = 10) did not differ in terms of original (mean ± SEM) blood pressure (159 ± 5/101 ± 1 ν 156 ± 4/103 ± 2 mm Hg), age (53 ± 2 ν 54 ± 2 years), sex distribution (5M:4F ν 7M:3F), or body mass index (24.4 ± 0.5 ν 24.2 ± 0.9 kg/m2). Blood pressure was also similar after 26 (137 ± 4/88 ± 1 ν 133 ± 3/90 ± 1 mm Hg) and 52 (137 ± 4/87 ± 1 ν 134 ± 4/89 ± 2 mm Hg) weeks of treatment. Plasma glucose and insulin responses decreased by 8 ± 3% (P < .05) and 25 ± 9% (P < .002), respectively, in cilazapril-treated patients, but did not change in those treated with cilazapril plus HC. Plasma triglyceride levels also tended to be lower by 13 ± 6% in those treated with cilazapril and higher in the cilazapril + HC-treated group by 15 ± 10%. The metabolic changes were seen by 26 weeks and stayed constant the remainder of the year. In conclusion, blood pressure fell in cilazapril-treated patients, associated with improvements in glucose, insulin, and lipid metabolism that would reduce risk of CHD. These changes could not be demonstrated when HC was added to cilazapril in order to achieve better control of blood pressure. These data suggest that the metabolic effects of antihypertensive drugs vary as a function of class of drug, independently of changes in blood pressure. Am J Hypertens 1992;5:506-510
No takes yet. Share an insight, caveat, or question.
Shieh et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: